Wall Street analyst estimates for Oruka Therapeutics, Inc. (ORKA): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | -$2.40 | 7 | ||
| 2027E | -$2.83 | 7 | ||
| 2028E | -$3.62 | 7 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 9 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 9 |
| Avg rating (−2 sell to +2 buy) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.60 | ||
| 2026-08-10 | $-0.55 | $-0.51 | -7.3% |
| 2026-05-13 | $-0.48 | $-0.55 | +12.2% |
| 2026-03-12 | $-0.45 | $-0.61 | +26.2% |
| 2025-11-12 | $-0.55 | $-0.56 | +1.8% |
| 2025-08-11 | $-0.46 | $-0.48 | +4.2% |
| 2025-05-14 | $-0.40 | $-0.57 | +29.8% |
| 2025-03-06 | $-0.49 | $-0.68 | +27.9% |
Valuation Ratios
| Price / Book | 5.62 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $24,000 | $27,000 | $22,000 | $89,000 | $93,000 | $91,000 | $114,000 | $111,000 | $27,000 | $83,000 |
| Gross Profit | -$24,000 | -$27,000 | -$22,000 | -$89,000 | -$93,000 | -$91,000 | -$114,000 | -$111,000 | -$27,000 | -$83,000 |
| Research & Development | $12.3M | $14.1M | $4.2M | $1.8M | $5.0M | $13.8M | $4.5M | $1.0M | $75.1M | $100.6M |
| Selling, General & Admin | $4.2M | $4.6M | $3.9M | $3.9M | $4.7M | $5.4M | $5.3M | $6.2M | $13.0M | $21.3M |
| Operating Expenses | $16.6M | $18.7M | $8.1M | $5.7M | $9.7M | $19.2M | $9.7M | $7.2M | $88.1M | $122.0M |
| Operating Income | -$16.6M | -$18.7M | -$8.1M | -$5.8M | -$9.8M | -$19.3M | -$9.8M | -$7.3M | -$88.1M | -$122.1M |
| EBITDA | -$16.4M | -$18.5M | -$7.9M | -$5.6M | -$9.6M | -$19.2M | -$9.8M | -$5.2M | -$82.2M | -$105.3M |
| Interest Expense | 0 | 0 | 0 | $7,000 | $9,000 | 0 | 0 | 0 | $1.5M | 0 |
| Pre-tax Income | -$16.4M | -$18.6M | -$8.0M | -$5.6M | -$9.7M | -$19.3M | -$9.9M | -$5.3M | -$83.7M | -$105.4M |
| Income Tax | 0 | -$61,000 | -$31,000 | -$167,000 | -$9,000 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$16.4M | -$18.5M | -$7.9M | -$5.5M | -$9.7M | -$19.3M | -$9.9M | -$5.3M | -$83.7M | -$105.4M |
| EPS | -$390.96 | -$382.87 | -$123.73 | -$49.79 | -$8.40 | -$16.68 | -$8.27 | -$4.44 | -$4.99 | -$2.31 |
| EPS (Diluted) | -$390.96 | -$382.87 | -$123.73 | -$49.79 | -$8.40 | -$16.68 | -$8.27 | -$4.44 | -$4.99 | -$2.31 |
| Shares Outstanding (Diluted) | 41,978 | 48,293 | 64,115 | 110,102 | 4.7 M | 13.9 M | 14.4 M | 14.4 M | 16.8 M | 45.6 M |
Price
| Price | $99.55 (closing price, November 3, 2026) |
| Market Cap | $6.6B |
| Exchange | NASDAQ |
| Country | US |
Related companies: DNTH · XNCR · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of ORKA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks